Licensing
Facilitating next-generation innovations to shape the future of medicine
The emergence of advanced, novel therapeutics has transformed the way pharmaceutical and biotech companies are approaching drug discovery and development. With the surge of cell, gene, and immunologic therapies, we are pleased to offer an extensive array of licensing opportunities designed to support you in developing your pipeline.
Proven expertise to multiply your impact:
- Scale your capacity to shorten setup periods and reduce development times
- Bolster your pharmaceutical projects with viral vector engineering and manufacturing and cell line engineering
- Expand your offerings by licensing IP like Pin-point (TM) Base Editing Platform, LentiBOOST® Viral vector-based gene editing, and more
For research use only. Not for use in diagnostic procedures.
Pin-point Base Editing Platform
Novel editing system for a more controlled approach to gene disruption and base correction with the potential for multiplex gene editing capabilities.
ご質問がございましたら、お気軽にお問い合わせください。
お問合せ